IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Buys 20,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 20,000 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was purchased at an average cost of $0.96 per share, with a total value of $19,200.00. Following the completion of the transaction, the insider owned 836,252 shares in the company, valued at $802,801.92. The trade was a 2.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Price Performance

Shares of IRIDEX stock opened at $0.88 on Thursday. IRIDEX Corporation has a 1-year low of $0.61 and a 1-year high of $1.65. The company has a market capitalization of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. The business has a 50-day moving average of $0.73 and a 200-day moving average of $0.95.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analyst estimates of $13.59 million. On average, equities analysts expect that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, IRIDEX has a consensus rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On IRIDEX

Several institutional investors and hedge funds have recently made changes to their positions in the company. Weber Capital Management LLC ADV bought a new position in IRIDEX during the second quarter worth $206,616. United Capital Financial Advisors LLC acquired a new position in IRIDEX in the second quarter worth $41,000. Diversify Advisory Services LLC bought a new stake in IRIDEX during the second quarter valued at $30,000. Diversify Wealth Management LLC bought a new stake in IRIDEX during the first quarter valued at $35,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of IRIDEX during the second quarter worth $29,000. 20.10% of the stock is owned by institutional investors and hedge funds.

IRIDEX News Summary

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.